エンパグリフロジンは,ストレプトゾトシン誘発の高血糖性男性ウィスターラットの学習と記憶の欠陥を改善します

Israa H Isawi¹, Nour A Al-Sawalha², Fatema Mahmoud²

¹Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.

Journal of experimental pharmacology

|February 19, 2026

まとめ

エンパグリフロジンは高血糖ラットにおける短期記憶を改善したが,長期記憶と酸化ストレスに対する影響は最小限であった. その神経保護機構を理解するためにさらなる研究が必要である.

科学分野:

神経科学は神経科学である.
エンドクリノロジーエンドクリノロジー
薬理学薬理学とは

背景:

エンパグリフロジン (Empa) のようなナトリウム・グルコースコトランスポーター2 (SGLT2) 阻害剤は,抗糖尿病薬である.
Empaは,グルコースコントロールを超えた抗酸化および抗炎症効果を示しています.
SGLT2は脳に存在し,高血糖症は認知機能低下と関連しています.

研究の目的:

ハイパーグリセミアのラットモデルでの学習と記憶に対するエンパグリフロジンの神経保護効果を調査する.
酸化ストレス,BDNF,NF-κBを含む潜在的なメカニズムを探求する.

主な方法:

シュレプトゾトシンを使用した男性Wistarラットで高血糖が誘発されました.
ネズミはエンパグリフロジンで治療を受けた.
認知機能は,ラジアルアームの水迷路を用いて評価されました.
ヒポキャンパスの酸化ストレスマーカー,BDNF,NF-κBを測定した.

主要な成果:

高血糖症のネズミは,学習と記憶の障害を示した.
エムパグリフロジンは短期記憶を大幅に改善しました.
長期記憶の改善は最小限であり,酸化ストレスマーカーであるBDNFやNF-κBの有意な変化はありませんでした.

結論:

ハイパーグリセミアの短期記憶に対するエンパグリフロジンの効果は,直接的な酸化ストレス軽減以外のメカニズムを含んでいる可能性があります.
高血糖症による認知障害における酸化ストレスと炎症の役割は複雑である.
エムパグリフロジンの神経保護機構を完全に解明するには,さらなる研究が必要です.

キーワード:

BDNF,BDNF,BDNFをはじめとする SGLT2 SGLT2 は,SGLT2 を使っている.動物モデル動物モデルコグニティブ障害 (Cognitive Impairment) とは,認知機能の低下によるヒポカンプス (海馬)

さらに関連する動画

05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

5.6K

06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

2.2K

関連する概念動画

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

関連する実験動画